Benzinga | Aug 27, 2020 08:25AM EDT

Seattle Genetics Highlights Data From Broad Oncology Portfolio During ESMO Virtual Congress 2020; Reports Positive Tisotumab Vedotin Phase 2 InnovaTV 204 Data In Recurrent Or Metastatic Cervical Cancer

Seattle Genetics Highlights Data from Broad Oncology Portfolio During ESMO Virtual Congress 2020

- Positive Tisotumab Vedotin Phase 2 innovaTV 204 Data in Recurrent or Metastatic Cervical Cancer to be Featured in Late-Breaking Oral Presentation -

- Data to be Presented from 11 Additional Abstracts Covering Marketed or Clinical-Stage Programs -

Seattle Genetics, Inc. (NASDAQ:SGEN) today announced the presentation of new data from its broad pipeline of marketed and investigational therapies at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, taking place September 19-21. Twelve abstracts, including a late-breaking abstract accepted for oral presentation featuring data from the positive tisotumab vedotin phase 2 innovaTV 204 clinical trial in recurrent or metastatic cervical cancer, will highlight the company's continued progress in advancing research in cancers that have a significant unmet need.

"At the ESMO Virtual Congress, we will be sharing important updates from our broad oncology portfolio of both marketed and investigational therapies, including an oral presentation of full data from the phase 2 trial evaluating tisotumab vedotin in recurrent or metastatic cervical cancer," said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. "In addition, we will present data describing real-world outcomes for patients with HER2-positive breast cancer with brain metastases, as well as additional analyses of the impact of TUKYSA on clinical outcomes and quality of life for patients in the HER2CLIMB trial. As illustrated by several trials in progress presentations, we continue to advance the development of our programs across a range of unmet medical needs."

The abstract titles published in advance of the ESMO Congress can be found here. All data presentations will be available via on-demand view starting on Thursday, September 17, 2020.

Details of Key Seattle Genetics Presentations at ESMO Virtual Congress 2020:

Abstract # / PresentationAbstract Title Presentation Presenter # Type / Date

Completed Clinical Trials

Tisotumab Vedotin

Tisotumab vedotin (TV) in previously Late-breakingtreated recurrent or metastatic oral RL.cervical cancer (r/mCC): results from #3435/#LBA32 presentation / Colemanthe phase 2 innovaTV 204/GOG-3023/ Monday, Sept. 21ENGOT-cx6 study at 17:04 CET

Tucatinib (TUKYSA(R))

Impact of Tucatinib on Health-Related OralQuality of Life (HRQoL) in Patients presentation / V.with HER2+ Metastatic Breast Cancer #2067/#275O Monday, Sept. 21 Mueller(MBC) with and without Brain Metastases at 12:42 CET(BM)

Impact of Tucatinib on Progression-Free PosterSurvival in Patients with HER2+ #2073/#293P presentation / T.Metastatic Breast Cancer and Brain Thursday, Sept. BachelotMetastases 17

Real-world outcomes among HER2+ Postermetastatic breast cancer patients with #4262/#308P presentation / N.brain metastases Thursday, Sept. Lindegger 17

Physiologically Based Pharmacokinetic Poster(PBPK) Modeling of the Central Nervous presentation /System (CNS) Pharmacokinetics of #3068/#295P Thursday, Sept. A. LeeTucatinib in Patients with Breast 17Cancer Brain Metastasis

Enfortumab Vedotin (PADCEV(R))

EV-201: Long-term results of enfortumab Postervedotin monotherapy for locally presentation / P.advanced or metastatic urothelial #2223/#746P Thursday, Sept. O'Donnellcancer previously treated with platinum 17and PD-1/PD-L1 inhibitors



Trials-in-Progress

Enfortumab Vedotin (PADCEV)

Study EV-302: A 3-arm, open-label,randomized phase 3 study of enfortumab Poster M. vanvedotin plus pembrolizumab and/or #2065/# presentation / derchemotherapy, versus chemotherapy 798TiP Thursday, Sept. Heijdenalone, in untreated locally advanced or 17metastatic urothelial cancer

Tucatinib (TUKYSA)

MOUNTAINEER: Open-Label, Phase 2 Study Posterof Tucatinib Combined with Trastuzumab #2070/# presentation / J.for HER2-Positive Metastatic Colorectal 523TiP Thursday, Sept. StricklerCancer 17

HER2CLIMB-02: A randomized, Posterdouble-blind, phase 3 study of #2068/# presentation / S.tucatinib or placebo with T DM1 for 353TiP Thursday, Sept. Hurvitzunresectable locally-advanced or 17metastatic HER2+ breast cancer

Other Investigational Therapies

innovaTV 208: New Weekly Dosing Cohort Posterin the Phase 2 Study of Tisotumab #2221/# presentation / SV. BlankVedotin in Platinum-Resistant Ovarian 882TiP Thursday, Sept.Cancer 17

SGNLVA-002: Single arm, open-label, Posterphase 1b/2 study of ladiratuzumab #2075/# presentation /vedotin (LV) in combination with 357TiP Thursday, Sept. J. Cortezpembrolizumab for first-line treatment 17of triple-negative breast cancer

SGNTGT-001: A phase 1 study of SGN?TGT, Posteran effector-function enhanced #2076/# presentation / E.monoclonal antibody (mAb), in advanced 1074TiP Thursday, Sept. Garraldamalignancies 17

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. ADCETRIS(r) (brentuximab vedotin) and PADCEV(r) (enfortumab vedotin-ejfv) use the Company's industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. TUKYSA(r) (tucatinib), a small molecule tyrosine kinase inhibitor, is approved in certain HER2-positive metastatic breast cancers. The company is headquartered in the Seattle, Washington area, with locations in California, Switzerland and the European Union. For more information on our robust pipeline, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the Company's pipeline and the advancement of its development programs across a range of unmet medical needs. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the difficulty and uncertainty of pharmaceutical product development, the risk of adverse events or safety signals, the inability to show sufficient activity in clinical trials and the possibility of adverse regulatory actions. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption "Risk Factors" included in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200827005253/en/